NCT03860272 2026-03-30
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT02423928 2019-10-25
CryoIT
Alden Cancer Therapy II
Phase 1 Completed
NCT02279862 2019-08-28
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Bristol-Myers Squibb
Phase 2 Completed
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00861614 2016-09-30
Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT01057810 2016-08-18
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT00323882 2014-08-28
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00050596 2011-06-27
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 2 Completed